{"id":"W2036532013","doi":"10.1016/j.jcte.2014.03.001","title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical & Translational Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Novo Nordisk; Sanofi; Eli Lilly and Company","keywords":"Lixisenatide; Sitagliptin; Medicine; Internal medicine; Postprandial; Dipeptidyl peptidase-4 inhibitor; Metformin; Glucagon-like peptide 1 receptor; Hypoglycemia; Endocrinology; Type 2 Diabetes Mellitus; Glycated hemoglobin; Type 2 diabetes; Sitagliptin Phosphate; Gastroenterology; Adverse effect; Clinical endpoint; Liraglutide; Diabetes mellitus; Agonist; Randomized controlled trial; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006028634,0.000193373,0.0006396161,0.0001166092,0.00007417195,0.00001608853,0.0002096296,0.00009545495,0.00006420855],"category_scores_gemma":[0.0005510476,0.0001070886,0.0002212072,0.0002088915,0.0004700758,0.0001083037,0.00005548129,0.000500469,0.000009115868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003597052,"about_ca_system_score_gemma":0.0001236969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008875544,"about_ca_topic_score_gemma":0.00009234244,"domain_scores_codex":[0.9974676,0.0003141312,0.001169014,0.0002278964,0.0005097309,0.0003115937],"domain_scores_gemma":[0.9969996,0.00180912,0.0005611895,0.0002601285,0.0002498878,0.000120036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009370772,0.001447436,0.9437062,0.00007092754,0.0008924083,0.000008822642,0.0003064796,0.0001593176,0.0002220741,0.001460071,0.0006838511,0.04167162],"study_design_scores_gemma":[0.01881943,0.002512735,0.9561936,0.0002467916,0.0003898253,0.000003599419,0.00004188505,0.00004990559,0.00009132742,0.0001640213,0.02137651,0.0001103352],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944548,0.0005732198,0.00001274428,0.002577895,0.000914894,0.0004576414,0.00001155043,0.000008224059,0.00098903],"genre_scores_gemma":[0.9979813,0.0004270071,0.0008926935,0.0002126536,0.0003108436,0.000005483676,0.00002218227,0.00002074596,0.000127095],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04156129,"threshold_uncertainty_score":0.4366948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01979462466269752,"score_gpt":0.2945601585356784,"score_spread":0.2747655338729809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}